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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent 
cancer worldwide with about 600,000 new cases diagnosed in the last year. The 
incidence of human papillomavirus-positive head and neck squamous cell carcinoma 
(HPV-positive HNSCC) has rapidly increased over the past 30 years prompting the 
suggestion that an epidemic may be on the horizon. Therefore, there is a clinical 
need to develop alternate therapeutic strategies to manage the growing number 
of HPV-positive HNSCC patients. TriCurin is a composition of three food-derived 
polyphenols in unique stoichiometric proportions consisting of curcumin from the 
spice turmeric, resveratrol from red grapes, and epicatechin gallate from green 
tea. Cell viability, clonogenic survival, and tumorsphere formation were inhibited 
and significant apoptosis was induced by TriCurin in UMSCC47 and UPCI:SCC090 
HPV-positive HNSCC cells. Moreover, TriCurin decreased HPV16E6 and HPV16E7 and 
increased p53 levels. In a pre-clinical animal model of HPV-positive HNSCC, intra-
tumoral injection of TriCurin significantly inhibited tumor growth by 85.5% compared 
to vehicle group (P < 0.05, n = 7). Our results demonstrate that TriCurin is a potent 
anti-tumor agent for HPV-positive HNSCC. Further development of TriCurin as a novel 
anti-cancer therapeutic to manage the HPV-positive HNSCC population is warranted.
INTRODUCTION
Approximately 600,000 new cases of head and 
neck squamous cell carcinoma (HNSCC) are diagnosed 
worldwide each year [1, 2]. These cancers are strongly 
associated with certain environmental and lifestyle risk 
factors, such as tobacco and alcohol consumption. More 
recently, high-risk human papillomavirus (HPV) infection, 
in particular HPV16, has emerged as an etiologic factor 
for the development of HNSCC [3]. Overall, about 25% 
of all HNSCC are positive for HPV DNA. HPV-positive 
HNSCC displays clinical and molecular features that 
distinguish it from the traditional alcohol- and smoking-
related HPV-negative HNSCC [4]. Retrospective and 
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prospective studies have shown that HPV-positive 
HNSCC patients have better response rates and clinical 
outcomes than HPV-negative HNSCC patients [5]. 
Standard of care treatment paradigms consisting of 
chemotherapy and/or radiation for HNSCC are fairly toxic 
and associated with high morbidity and quality of life 
issues. Based on these concerns, there were discussions 
and now clinical trials designed to assess the impact of 
treatment de-intensification strategies for the HPV-positive 
HNSCC population. Alternatively, novel less-toxic 
therapeutic approaches need to be developed to add to the 
armamentarium to manage HPV-positive HNSCC patients.
Several pre-clinical studies reported that natural 
phenolic compounds have anti-HPV and anti-cancer 
activity [6, 7]. Plant phenols play an important role in 
cancer prevention. Epidemiologic studies show diets 
high in these polyphenol-rich foods, such as vegetables 
and fruits, are associated with reduced cancer rates [8]. 
Curcumin is a polyphenol extracted from the food spice 
turmeric. In China and India, turmeric has been used as 
medicinal herb to treat various ailments over the centuries. 
Numerous scientific reports have shown that curcumin 
has anti-cancer activity and targets numerous oncogenic 
pathways [9–12]. Our group demonstrated that curcumin 
eliminates various HPV-positive cervical carcinoma cell 
lines and is non-toxic to healthy tissue [13]. Resveratrol 
is a polyphenol found in grapes, it is also a potent 
antioxidant [14–17] with anti-inflammatory and cancer-
preventive [18–21] properties. Studies reported that both 
curcumin and resveratrol displayed synergistic effects with 
cancer therapeutics [22–24]. Epicatechin gallate is one of 
the major catechins in green tea and also has shown anti-
cancer activity on a variety of cell types [25]. Although 
pre-clinical studies show these polyphenols as promising 
anti-cancer compounds, clinical trials evaluating 
curcumin, epicatechins, and resveratrol have had only 
marginal results due to poor bioavailability and low target 
tissue uptake [26, 27]. 
To overcome the clinical challenge associated with 
developing polyphenols as a therapeutic, TriCurin, a triple 
polyphenol combination consisting of curcumin, epicatechin 
gallate, and resveratrol in specific stoichiometric proportions, 
was formulated to maximize anti-tumor activity. In this 
study, TriCurin was highly active to eliminate HPV-positive 
HNSCC cells in vitro and in vivo. Our work provides initial 
evidence that TriCurin may be a promising therapeutic to 
manage HPV-positive HNSCC patients.
RESULTS
TriCurin promotes a global anti-tumor response 
in HPV-positive HNSCC
Two HPV16-positive HNSCC cell lines, UMSCC47 
and UPCI:SCC090, were tested for growth inhibition 
using a dose range of TriCurin (Figure 1A). The IC50 
was calculated to be 3.22 µM+ and 1.86 µM+ for 
UMSCC47 and UPCI:SCC090, respectively. TriCurin 
(3 µM+ for 72 hours) promoted apoptosis in both 
HPV16-positive HNSCC cell lines (Figure 1B). In 
comparison with vehicle, TriCurin induced 66.1 
± 3.6% apoptosis in UMSCC47 (P < 0.01, n = 3), 
and 11.8 ± 0.7% apoptosis in UPCI:SCC090 cells 
(P < 0.01, n = 3). Clonogenic survival assay was used 
to assess the clonal proliferation of surviving cells 
over a prolonged time-period. As shown in Figure 1C, 
clonogenic survival of UMSCC47 and UPCI:SCC090 
cells was compromised with TriCurin treatment (3 
µM+ for 24 hours); 66.7 ± 3.0% (P < 0.01, n = 3) 
inhibition for UMSCC47 and 92.4 ± 1.0% inhibition 
for UPCI:SCC090 (P < 0.01, n = 3). Moreover, the 
combination of TriCurin and radiation was more 
active (P < 0.01, n = 3) than either single intervention 
to ablate UMSCC47 cells (Supplementary Figure 
1). Radiation (3 Gy) reduced clonogenic survival of 
UMSCC47 cells by 44.8 ± 1.7% whereas the TriCurin 
and radiation combination decreased the number of 
survival clones by 79.9 ± 3.6%. The ability of cells to 
form spheres under non-adherent culture conditions has 
been widely used as an in vitro assay to assess normal 
stem cells and cancer initiating cells (CICs). Our group 
showed that tumorspheres are enriched for CICs and a 
single tumorsphere has the potential to generate a bulky 
tumor in vivo [28]. Tumorsphere formation efficiency 
was reduced in a dose-dependent manner with TriCurin 
treatment (Figure 1D). At the highest concentration 
(10 µM+), TriCurin decreased tumorsphere formation 
efficiency by 66.1 ± 7.8% (P < 0.01, n = 3) in 
UMSCC47 and 56.7 ± 4.7% (P < 0.01, n = 3) 
in UPCI:SCC090. In addition, TriCurin reduced 
tumorsphere diameter by 16.0 ± 0.8% (P < 0.05, n = 3) 
in UMSCC47 and 19.4 ± 0.3% (P < 0.05, n = 3) in 
UPCI:SCC090 (Figure 1E).
TriCurin reduces HPV16E6/E7 and enhances 
p53/Rb levels in HPV-positive HNSCC
It is well recognized that HPV16 oncogenes, 
E6 and E7, inactivates p53 and Rb, respectively, to 
drive HPV- induced carcinogenesis. shRNA-mediated 
knockdown of HPV16E6/E7 is sufficient to promote 
apoptosis and ablate HPV16-positive HNSCC cells 
[29]. Therefore, we determined if the global anti-tumor 
effect of TriCurin is mediated through suppression 
of HPV16E6/E7. In Figure 2, TriCurin treatment 
dramatically reduced HPV16E6 and HPV16E7 mRNA 
expression and protein levels in UMSCC47 and 
UPCI:SCC090 cells. Moreover, an increase in p53 and 
Rb levels were observed following TriCurin treatment. 
These results confirm that TriCurin targets HPV16E6/
E7 resulting in an accumulation of p53 and Rb in HPV-
positive UMSCC47 and UPCI:SCC090 cells.
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TriCurin retards tumor growth in vivo
The in vivo activity of TriCurin was assessed in a 
pre-clinical mouse model of HPV16-positive HNSCC. 
UMSCC47 cells were implanted into the flanks of 
athymic nude mice and allowed to establish without 
treatment. At 41 days post-tumor cell implantation, mice 
with established tumors were randomly assigned to 
two treatment arms; vehicle or TriCurin (3×/week for 
5 weeks). Intra-tumor therapy for the treatment of HNSCC 
has been previously proposed using gene therapy [30]. 
Though only limited effects have been seen in these phase 1 
and 2 clinical trials [31], the feasibility of doing intra-tumor 
treatment was validated in the clinical setting. Intra-tumoral 
Figure 1: TriCurin promotes a global anti-tumor response in HPV-positive HNSCC. (A) IC50. The MTS reagent was used 
to measure cell proliferation. Dose response curve and IC50 of TriCurin were generated using GraphPad Prism software. (B) Apoptosis. 
UMSCC47 and UPCI:SCC090 cells were treated with control or TriCurin (3 µM+). Cells were stained with FITC-Annexin V and propidium 
iodide and analyzed by flow cytometry. Data are presented as mean ± SEM. *P < 0.01, n = 3. (C) Clonogenic survival. UMSCC47 and 
UPCI:SCC090 cells were treated with control or TriCurin (3 µM+). The number of surviving clones was assessed by counting the number 
of clones under a microscope after crystal violet staining. A representative well for each experimental condition is shown and data are 
presented as mean ± SEM. *P < 0.01, n = 3. (D) Tumorsphere formation efficiency and diameter. UMSCC47 and UPCI:SCC090 cells 
were treated with control or TriCurin (1, 3, or 10 µM+) and cultured in ultralow attachment plates. Tumorsphere formation efficiency was 
calculated as the number of tumorspheres formed divided by the original number of cells seeded. Tumorsphere diameter was measured 
using NIS-Elements software. Data are presented as mean ± SEM. *P < 0.01, n = 3 for tumorsphere formation efficiency. *P < 0.05, n = 3 
for tumorsphere diameter.
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delivery of TriCurin inhibited tumor growth by 85.5% (P 
< 0.05, n = 7) (Figure 3A). At the end of the treatment 
protocol, mice were sacrificed and tumors were resected 
and weighed. TriCurin reduced the tumor weight by 86.3% 
(P < 0.01, n = 7); the mean tumor weight was 904.3 ± 
203 and 123.5 ± 42.8 mgs for the vehicle and TriCurin, 
respectively (Figure 3B). Analysis of the H&E stained 
tumor sections from the TriCurin group showed that the 
majority of the tumor consisted of large necrotic areas 
with small regions of tumor cells present in the tumor 
periphery (Figure 3C). In contrast, as shown in Figure 3D, 
the tumors from the vehicle group were multi-lobulated 
and predominantly populated with tumor cells. The 
vehicle-treated tumors also had regions of necrosis but 
comparatively much less necrotic tissue than the TriCurin-
treated tumors. Ki67 immunohistochemical staining 
showed that TriCurin treatment reduced the number of 
actively proliferating tumor cells by 19.9% (P < 0.003) 
compared to vehicle (Figure 3E). Furthermore, TriCurin 
dramatically reduced the intra-tumoral levels of HPV16E6 
(94.9% inhibition, P < 0.001) (Figure 4).
DISCUSSION
HNSCC encompasses many site-specific cancers, 
including oral cavity and oropharyngeal cancers. Alcohol 
Figure 2: TriCurin reduces HPV16E6/E7 and enhances p53/Rb levels in HPV-positive HNSCC. UMSCC47 and 
UPCI:SCC090 cells were treated with control or TriCurin (3 µM+ for 72 hours. (A) HPV16E6/E7 and p53/Rb mRNA expression. mRNA 
expression was determined by qRT-PCR. Data were normalized to GAPDH and presented as mean ± SEM. *P < 0.001, n = 5. (B) HPV16E6/
E7 and p53/Rb protein levels. Protein levels were determined by immunoblot analyses. 
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and tobacco are the traditional risk factors for HNSCC 
and incidence rates are found to be higher in regions 
with high rates of alcohol and tobacco consumption 
[32]. During the past few decades, several countries have 
witnessed a decline in oral cavity cancer incidence due 
to a decline in tobacco use. However, Canada, Denmark, 
the Netherlands, Norway, Sweden, the United States, 
and the United Kingdom, have seen an increasing rate of 
oropharyngeal and oral cavity cancers despite declines in 
smoking rates since the 1980s. The increase in HNSCC 
incidence rate in these developed countries is attributed to 
HPV, in particular high-risk HPV16 [33]. It is estimated 
that by 2025, the number of new HPV-positive HSNCC 
cases will be similar if not greater than the number of 
new HPV-positive cervical cases. Thus, there is a critical 
need to develop novel therapeutic strategies to better 
manage the growing number of HPV-positive HNSCC 
population. 
Figure 3: TriCurin retards tumor growth in a pre-clinical model of HPV-positive HNSCC. (A) Tumor volume. UMSCC47 
cells were implanted into the flanks of athymic nude mice and tumors were allowed to develop without treatment. At 41 days post-tumor 
cell implantation, mice with palpable tumors were randomly assigned to two treatment arms: vehicle or TriCurin (3×/week for 5 weeks). 
Tumors were measured using a digital caliper and tumor volumes were calculated. Data are presented as mean ± SEM. *P < 0.05, n = 7. 
(B) Tumor weight. Mice were sacrificed at the end of the treatment protocol and tumors were resected and weighed. Data are presented 
as mean ± SEM. *P < 0.01, n = 7. (C) H&E histopathology. A representative image from a tumor in the control or TriCurin-treated group 
is shown. Tumors from TriCurin-treated mice showed large necrotic areas (yellow arrows) with residual tumor cells (green arrows) in the 
periphery. Tumors from control-treated mice were multi-lobulated with large areas populated with residual tumor cells. (D) Ki67 staining. 
Typical areas for each case were photographed with a 20× objective lens and shown.  The Ki67 labeling index was scored as the percentage 
of tumor cell nuclei showing definite nuclear immunoreactivity above the background level using Image J. Data are presented as mean ± 
SEM. *P < 0.003. 
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Figure 4: TriCurin reduces intra-tumoral levels of HPV16E6. Representative immunofluorescence images from a tumor in 
the control or TriCurin-treated group are shown (scale bar: 300 µm). Nuclear staining with HOECHST33342 was used to normalize for 
HPV16E6 staining intensity. Data are presented as mean ± SEM. *P < 0.001.
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Polyphenols are present in foods and beverages 
of plant origin (fruits, vegetables, cereals, herbs, spices, 
legumes, nuts, olives, chocolate, tea, coffee, and wine) and 
are the most abundant antioxidants in the human diet [34]. 
Polyphenols show many beneficial effects on human health 
including antimicrobial, anti-inflammatory, anti-viral, anti-
tumoral, and immunomodulatory activities [35–39]. One 
of the most potent and promising anti-tumor polyphenols 
reported in preclinical studies is curcumin [10, 11]. 
Curcumin has been shown to promote apoptosis through 
PARP-dependent and PARP-independent pathways. 
Recent work revealed a role for apoptosis inducing factor 
in curcumin-mediated apoptosis [40]. These results 
demonstrate that curcumin-mediated cell death is complex 
and may involve multiple apoptotic pathways. Our group 
demonstrated that curcumin effectively eliminates various 
HPV-positive cervical carcinoma cell lines in vitro; prior 
to cell death, curcumin simultaneously decreased HPVE6 
levels and induced the expression of p53 [13]. The anti-
tumor effect of curcumin was not HPV-type specific, 
showing activity against high-risk HPV genotypes 16, 
18, and 68. Similarly, the polyphenols extracted from 
green tea, catechins, have shown potent activity against 
HPV-positive carcinoma cells. Catechins inhibit cell 
proliferation in a dose-dependent manner and directly 
inhibit HPVE6 and HPVE7 [41]. Resveratrol is another 
polyphenol with anti-tumor activity and promotes cell 
cycle arrest and apoptosis in HPV-positive cervical 
carcinoma cells [7]. These plant-derived polyphenols 
demonstrated promising pre-clinical efficacy; however, 
curcumin, catechins, and resveratrol have not advanced 
beyond clinical trials due to limitations, such as rapid 
metabolism and low target tissue bioavailability.
Our previous work demonstrated that single-agent 
curcumin, epicatechin gallate, or resveratrol inhibits 
proliferation and E6 levels in HPV-positive HeLa cervical 
carcinoma [42, 43]. Combination therapy of curcumin, 
epicathechin gallate, and resveratrol at their IC50 doses 
(16 µM, 16 µM, and 65 µM, respectively) showed general 
toxicity and did not discriminate between HeLa cells 
and normal fibroblasts [42]. Comprehensive single-, 
double-, and triple-agent studies revealed that curcumin, 
epicatechin gallate, and resveratrol at a defined molar 
ratio of 4:1:12.5 (TriCurin) was selective to ablate HeLa 
cells and furthermore, more active than each individual 
component or the doublet of curcumin and epicatechin 
gallate or curcumin and resveratrol [42]. Moreover, 
intra-lesional administration of TriCurin was highly 
active and inhibited in vivo tumor growth of HPV16E6/
E7, c-Ha-ras-expressing TC-1 cells by 80% [42]. In the 
present study, TriCurin exhibited high anti-tumor activity 
in vitro and in vivo against HPV16-positive HNSCC 
cells. HPV16E6 and HPV16E7 levels were dramatically 
reduced, whereas, p53 and Rb levels were increased 
with TriCurin treatment. Since HPV16E6 and HPV16E7 
oncogenic proteins are essential for cell transformation 
and tumor cell maintenance, we suggest that a potential 
mechanism of action of TriCurin in HPV16-positive 
HNSCC cells is through reduction of the HPV16E6/E7 
viral proteins. Our in vivo data show that intra-tumor 
delivery of TriCurin results in a large amount of tumor 
cell death in the region of the injection site. Furthermore, 
tumor cells in the periphery of the tumor showed an altered 
phenotype with decrease Ki67 staining and a significant 
decrease in the levels of the viral oncogenic HPV16E6 
protein. Radiation is a standard of care for HNSCC 
patients and the observation that TriCurin potentiates the 
anti-tumor efficacy of radiation provides initial evidence 
that the TriCurin and radiation combination should be 
extensively explored in future studies. Taken together, our 
findings provide initial evidence that TriCurin may be an 




Detailed description of the development of TriCurin 
has been described [42]. Briefly, curcumin, epicatechin 
gallate, and resveratrol at the molar proportion 4:1:12.5 
were prepared at various doses. A solution of 1.28 mM+ 
TriCurin (1.28 mM curcumin:0.32 mM epicatechin 
gallate:4 mM resveratrol) in PBS plus 0.1% DMSO 
was prepared by dilution from solutions of curcumin 
and resveratrol in DMSO and a solution of epicatechin 
gallate in PBS. Subsequently, 64 µM+, 32 µM+, 16 µM+, 
8 µM+, 4 µM+, 2 µM+ and 1 µM+ TriCurin solutions 
were prepared through serial dilutions of the 1.28 mM+ 
in PBS. For the treatment of cells to determine IC50, 
TriCurin was diluted in the corresponding culture medium.
Cell culture
UMSCC47 and UPCI:SCC090 HPV16-positive 
HNSCC cells were obtained from Dr. Thomas Carey 
(University of Michigan) and Dr. Susanne Gollin 
(University of Pittsburgh), respectively. Cells were 
maintained at 37°C, 5% CO2 and 95% humidity in 
Dulbecco’s modified Eagle’s medium containing 10% 
(v/v) fetal bovine serum (BioWhittaker, Walkersville, 
Maryland, USA), 100 units/ml penicillin and 1000 µg/ml 
streptomycin (Invitrogen, Carlsbad, California, USA). 
Cell lines were authenticated using short tandem repeat 
profiling every six months by our research group. 
MTS assay
The sensitivity of cells to TriCurin was measured 
using the MTT-based colorimetric cell proliferation kit 
(Roche Applied Science, Mannheim, Germany). Briefly, 
3000 cells/well were plated in a 96 well plate. The next 
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day, cells were treated with different concentrations of 
TriCurin. After 72 hours, 10 µL/well of MTT solution 
was added to each well and further incubated for 4 hours 
at 37°C. The formazan crystals formed in the wells 
were solubilized by adding solubilization solution and 
incubating the plates for 4 hr at 37°C. The plates were read 
at 490 nm on a Spectramax 190 plate reader (Molecular 
Devices Inc., Sunnyvale, CA). The percentage cell growth 
inhibition for each treatment group was calculated by 
adjusting the untreated control group to 100%. Data were 
analyzed using GraphPad Prism software (GraphPad 
Software, Inc., San Diego, CA) and the dose response 
curves were used to calculate the concentration of TriCurin 
resulting in 50% inhibition of cell proliferation (IC50) 
using a four parametric logistical model. All experiments 
were repeated at least 3 times.
Apoptosis analysis
Cells were plated in 6-well plate and incubated 
with vehicle or TriCurin (3 µM) for 72 hours. Cells were 
stained with FITC-Annexin V and propidium iodide (Life 
Technologies, OR, USA) and analyzed by flow cytometry.
Clonogenic survival assay
Cells were incubated with vehicle or TriCurin for 
24 hours (3 µM), harvested and collected, then suspended 
in complete growth medium. Cells were seeded onto 
6-well plates and allowed to grow until visible colonies 
formed (7–10 days). The cell colonies were fixed with 
cold methanol, stained with 0.25% crystal violet in 25% 
methanol, washed and air-dried.
Tumorsphere formation assay
Cells were incubated with vehicle TriCurin for 24 
hours (1, 3, 10 µM), harvested, and collected and washed 
to remove serum, then suspended in serum free DMEM/
F12 supplemented with 1% antibiotic-antimycotic (Life 
Technologies, OR, USA), 20 ng/mL human recombinant 
epidermal growth factor (hrEGF), 10 ng/mL human 
recombinant basic fibroblast growth factor (hrbFGF), 2% 
B27 supplement (Invitrogen, Carlsbad, CA, USA), 1% N2 
supplement (Invitrogen, Carlsbad, CA, USA). Subsequently, 
cells were cultured in ultralow attachment 96-well plates 
(Corning Inc., Corning, NY, USA) for tumorsphere formation. 
Quantitative real-time reverse transcription PCR
Real-time reverse transcription PCR was performed 
using real-time PCR universal reagent and ABI-7900HT 
real-time PCR machine (Applied Biosystems). All 
reactions were done in a 20 µl reaction volume in triplicate 
using validated TaqMan Gene Expression Assays for p53, 
HPV16E6, HPV16E7, and GAPDH. PCR amplification 
consisted of an initial denaturation step at 95°C for 
10 minutes, followed by 40 cycles of PCR at 95°C for 
15 seconds, 60°C for 60 seconds. Standard curves were 
generated and the relative amount of p53, HPV16E6, and 
HPV16E7 was normalized to GAPDH, respectively.
Western blot analysis
Whole cell lysates were mixed with Laemmli 
loading buffer, boiled, separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, and transferred 
to a PVDF membrane. Subsequently, immunoblot 
analyses were performed using antibodies specific to 
p53 (Calbiochem, San Diego, CA), HPV16E6 (Abcam, 
Cambridge, MA), HPV16E7 (Cervimax, Vienna, Austria), 
or GADPH (Cell Signaling Technology, Danvers, MA). 
The signal was developed with ECL (Thermo Fisher 
Scientific) after incubation with appropriate secondary 
antibodies.
Pre-clinical model of HPV-positive HNSCC
Athymic nude (NCr) mice were purchased from 
Charles River Laboratories (Wilmington, MA) and housed 
at The Ohio State University animal facility. Animals were 
allowed to acclimate for 1 week prior to experimentation. 
All animal work performed was in accordance with 
and approved by the Institutional Animal Care and Use 
Committee at The Ohio State University. UMSCC47 cells 
grown to 80% confluence were harvested, and the cells 
(1 × 106) mixed with Matrigel (1:1) were implanted into 
the flanks of 8-week old female athymic nude mice and 
tumors were allowed to develop without treatment. At 
41 days after implantation, mice with palpable tumors 
were assigned to two experimental groups and treated 
with 0.1% DMSO in PBS-control or 1.28 µM+ TriCurin (5 
µL, three times per weekly, n = 7) by direct intra-tumoral 
injection. Tumors were measured using a digital caliper 
and tumor volumes were calculated using the formula: 
tumor volume = length × width × height × 0.5. 
Immunohistochemistry
After the treatment protocol, the mice in both 
experimental groups were sacrificed and the entire 
tumors were resected. About two-thirds of each tumor 
was fixed in 4% paraformaldehyde. The formalin-fixed, 
paraffin-embedded tissues were sectioned at 4 microns 
and stained with hematoxylin and eosin (H&E) for 
histologic examination. Immunohistochemistry for Ki67 
levels was performed using an antibody against the 
C-terminal portion of Ki67 (Catalog # 790-2910, Ventana 
Medical Systems Inc., Tucson, AZ). Immunostaining was 
performed on an autoimmunostainer (Ventana XT System 
Benchmark; Ventana Medical Systems) according to the 
manufacturer’s recommendations. Ki67 immunostaining 
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was evaluated by two pathologists.  The typical areas 
for each case were photographed with a 20× objective 
lens using a Nikon microscope and digital camera DS-
L3 (Nikon, Tokyo, Japan).  The Ki67 labeling index was 
scored as the percentage of tumor cell nuclei showing 
definite nuclear immunoreactivity above the background 
level using Image J (National Institute of Health). 
About a third of each excised tumor was processed for 
immunofluorescence staining for HPV16/18E6. Coronal 
sections (30 µm) were made from 4% paraformaldehyde-
fixed and 30% sucrose-soaked tumors. Tumor sections of 
three animals from each group were processed as follows 
for antigen retrieval: incubation with formamide 2 × SSC 
(1:1), 55°C for 2 h, and then 5 min in 2 × SSC (NaCl 
and sodium citrate) at room temperature. After blocking 
overnight at 4°C in 0.1 % Triton X-100, 3% goat serum 
in 100 mM phosphate buffered saline (PBS), the sections 
were treated overnight with primary antibody: HPV16/18 
E6 (C1P5; sc-460) (1:100), (diluted in 2% goat serum and 
0.1% Triton X-100 in PBS). Secondary antibody control 
sections were incubated overnight at 4°C in blocking 
solution. After washing three times with PBS, the goat 
anti-mouse-488 secondary antibody (Invitrogen-Molecular 
Probes) (1:1000 dilution) was added to the primary 
antibody-treated as well as secondary control sections. 
Following overnight incubation at 4°C and three washes 
with PBS, the sections were treated with HOECHST33342 
(10 µg/ml) for 30 min at room temperature. Next, the 
sections were washed three times with PBS and mounted 
on microscope slides with Gold anti-fade mounting fluid 
(Invitrogen-Molecular Probes). Confocal imaging was 
conducted using a Leica SP2 microscope. ImageJ was 
used to obtain the HPV16/18E6 and HOECHST33342 
fluorescence intensity. HPV16/18E6 intensity (green) was 
normalized to HOECHST33342 intensity (blue).
Statistical analysis
The statistical significance of the results was 
evaluated using ANOVA and a Student’s t-test. P-value 
< 0.05 was considered significant.
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